Yonah S. Tehrani: Providing Clarity for Anticoagulant Selection in Acute Venous Thromboembolism
Yonah S. Tehrani, Physician at Shaare Zedek Medical Center, Jerusalem, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published in New England Journal of Medicine:
”Recent head-to-head data from the COBRRA trial (NEJM, March 2026) provides much-needed clarity for anticoagulant selection in acute venous thromboembolism.
In this randomized study of >2,700 patients with symptomatic PE or proximal DVT, apixaban (standard dosing) was associated with a significantly lower rate of clinically relevant bleeding compared with rivaroxaban over 3 months (3.3% vs 7.1%; RR 0.46, p<0.001), with no difference in recurrent VTE.
These findings have direct implications for daily clinical decision-making: when balancing efficacy and safety — particularly in older adults, patients with renal impairment, or those at elevated bleeding risk — apixaban now offers a clear safety advantage without compromising antithrombotic protection.
At the system level, preferential use could translate to reduced bleeding-related hospitalizations, lower transfusion rates, and more confident outpatient PE management.
Important to note the open-label design and potential contribution of dosing regimen differences, but the magnitude of effect is clinically meaningful and should inform local protocols and shared decision-making discussions.
What are your thoughts?
Has this data already shifted prescribing patterns in your institution?
Looking forward to the discussion.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS